Dr. Agarwal’s Health Care Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Dr. Agarwal’s Health Care Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Dr. Agarwal’s Health Care shares trading at Rs.474 against a market capitalisation of Rs.15,099 Cr and a price-to-earnings multiple of 89.9. As an industrials and capital goods name on the NSE and BSE, Dr. Agarwal’s Health Care enters the Dr. Agarwal’s Health Care Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Dr. Agarwal’s Health Care Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.501 Cr revenue and Rs.38 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Dr. Agarwal’s Health Care Research at Univest

About Dr. Agarwal’s Health Care

Dr. Agarwal’s Health Care (NSE: AGARWALEYE) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings. Ahead of the Dr. Agarwal’s Health Care Q1 Results FY27 print, the company’s Q4 FY26 base shows revenue of Rs.577 Cr and net profit of Rs.50 Cr, forming the base against which the Dr. Agarwal’s Health Care Q1 Results FY27 estimates in this article are built. This Dr. Agarwal’s Health Care Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Dr. Agarwal’s Health Care Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	565-650	501	+21.2%
Net Profit / PAT (Rs. Cr)	39-50	38	+17.4%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.551-613

Univest, a SEBI-Registered Investment Advisor, Tracks Dr. Agarwal’s Health Care Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Order Book Execution

Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of Dr. Agarwal’s Health Care’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Dr. Agarwal’s Health Care share price target or faces renewed pressure.

2. Capex Revival in User Industries

Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of Dr. Agarwal’s Health Care’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Dr. Agarwal’s Health Care share price target or faces renewed pressure.

3. Operating Leverage

Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of Dr. Agarwal’s Health Care’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Dr. Agarwal’s Health Care share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Dr. Agarwal’s Health Care’s live price and Q1 FY27 result updates.

Key Risks to the Dr. Agarwal’s Health Care Q1 Results FY27 Outlook

• Order execution delays pushing revenue recognition to later quarters.
• Raw material and input cost inflation pressuring margins.
• Slower capex recovery in key end-user industries affecting order inflows.

Q4 FY26 Performance Context for the Dr. Agarwal’s Health Care Q1 Results FY27 Print

Dr. Agarwal’s Health Care closed Q4 FY26 with revenue of Rs.577 Cr and net profit of Rs.50 Cr, a year-on-year revenue change of +21.2% and PAT change of +17.4%. This base underpins the Dr. Agarwal’s Health Care Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Dr. Agarwal’s Health Care Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Dr. Agarwal’s Health Care Q1 Results FY27

Dr. Agarwal’s Health Care shares last traded at Rs.474. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Dr. Agarwal’s Health Care Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Dr. Agarwal’s Health Care Q1 Results FY27 trailing-growth framework points to a range of Rs.490-528 for Dr. Agarwal’s Health Care, contingent on the Dr. Agarwal’s Health Care Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Dr. Agarwal’s Health Care Q1 Results FY27 view for Dr. Agarwal’s Health Care works out to Rs.551-613, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Dr. Agarwal’s Health Care Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Dr. Agarwal’s Health Care Q1 Results FY27 analysis would put Dr. Agarwal’s Health Care in a Rs.621-707 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Dr. Agarwal’s Health Care Q1 Results FY27 Print

• Revenue and PAT versus the Dr. Agarwal’s Health Care Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Dr. Agarwal’s Health Care Q1 Results FY27 narrative.
• Healthy order book execution translating into revenue recognition for the quarter
• Order execution delays pushing revenue recognition to later quarters

Conclusion on Dr. Agarwal’s Health Care Q1 Results FY27

Dr. Agarwal’s Health Care enters the Q1 FY27 results season trading at Rs.474, with the 12-month Uniresearch target range of Rs.551-613 reflecting a tracking with a constructive bias stance. Investors tracking the Dr. Agarwal’s Health Care Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Dr. Agarwal’s Health Care Q1 Results FY27

When are Dr. Agarwal’s Health Care Q1 FY27 results expected?

Ans. Dr. Agarwal’s Health Care’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Dr. Agarwal’s Health Care Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Dr. Agarwal’s Health Care’s Q1 FY27 revenue is Rs.565-650 Cr, based on the Q1 FY26 base of Rs.501 Cr.

What is the Dr. Agarwal’s Health Care share price target?

Ans. The 12-month Uniresearch estimate for Dr. Agarwal’s Health Care share price target is Rs.551-613, based on trailing growth and current valuation multiples.

Is Dr. Agarwal’s Health Care a good buy before Q1 FY27 results?

Ans. Dr. Agarwal’s Health Care is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Dr. Agarwal’s Health Care’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.

Where can I track Dr. Agarwal’s Health Care share price live?

Ans. Dr. Agarwal’s Health Care share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.